The combination of talquetamab (Talvey) and daratumumab (Darzalex) demonstrated promising and robust clinical activity for ...
Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...
INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...
Recordati Rare Diseases Inc. today announced the presentation of new data related to its growing portfolio of treatments for rare hematologic disorders at the 67th American Society of Hematology (ASH) ...
Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 ...
Next-Generation Biopharmaceuticals Transforming the Global Therapeutic LandscapeThe Global Bio Pharmaceuticals Market is ...
Gilead Sciences, Inc. and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback